Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bioequivalence Study of Two Formulations of Perindopril 4 mg Tablet Under Fasting Condition

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01682577
Recruitment Status : Completed
First Posted : September 11, 2012
Last Update Posted : September 11, 2012
Sponsor:
Information provided by (Responsible Party):
Dexa Medica Group

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The objective of this study was to find out whether the bioavailability of PT Dexa Medica's formulation of 4 mg perindopril tert-butylamine tablets was equivalent to that of the innovator's product (Prexum® 4 mg, Servier).

Condition or disease Intervention/treatment Phase
Healthy Drug: Perindopril 4 mg tablets of PT Dexa Medica Drug: Perindopril 4 mg tablets of Servier Not Applicable

Detailed Description:

The participating subjects were required to have an overnight fast and in the next morning were given orally one tablet of the test drug (Perindopril 4 mg tablets of PT Dexa Medica) or one tablet of the reference drug (Prexum® 4 mg, Servier).

Blood samples were drawn immediately before taking the drug (control), and at 20, 40 minutes, and 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, 192 hours after drug administration.

Three weeks after the first drug administration (washout period), the procedure was repeated using the alternate drug.

The pharmacokinetic parameters, including AUCt, AUCinf, Cmax, t max, and t1/2, were determined based on the concentrations of the perindopril parent compound and the metabolite perindoprilat, using high-performance liquid chromatography method with tandem mass spectrometry detector (LC-MS/MS).

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: Bioequivalence Study of 4 mg Perindopril Tablets Produced by PT Dexa Medica in Comparison With the Reference Tablets (Prexum® 4 mg, Servier)Under Fasting Condition
Study Start Date : September 2008
Actual Primary Completion Date : November 2008
Actual Study Completion Date : December 2008

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Perindopril 4 mg tablets of PT Dexa Medica

Group I (Test product): each tablet contains perindopril tert-butylamine salt 4 mg.

A single dose of perindopril tablet of PT Dexa Medica was given to each of study subjects.

 Drug: Perindopril 4 mg tablets of PT Dexa Medica
Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
Other Names:
  • Test Product: Perindopril 4 mg tablets of PT Dexa Medica.
  • Each tablet contains perindopril tert-butylamine salt 4 mg
Active Comparator: Perindopril 4 mg tablets of Servier

Group II (Reference product) : each tablet contains perindopril tert-butylamine salt 4 mg.

A single dose of perindopril (Prexum) tablets of Servier was given to each of study subjects.

 Drug: Perindopril 4 mg tablets of Servier
Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
Other Names:
  • Reference product: Prexum® 4 mg, produced by Servier.
  • Each tablet contains Perindopril tert-butylamine salt 4 mg.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Area under concentration-time curve (AUC)of perindopril parent compound [ Time Frame: 192 hours ]
    Relative bioavailability (primarily measured by AUCt and AUCinf) between two perindopril 4 mg tablet formulations (test and reference formulations) under fasting condition. The AUC was measured based on the plasma concentration of perindopril parent compound.

  2. Area under concentration-time curve (AUC)of perindoprilat [ Time Frame: 192 hours ]
    Relative bioavailability (primarily measured by AUCt and AUCinf) between two perindopril 4 mg tablet formulations (test and reference formulations) under fasting condition. The AUC was measured based on the plasma concentration of the active metabolite, perindoprilat.


Secondary Outcome Measures :
  1. Peak plasma concentration (Cmax)of perindopril parent compound [ Time Frame: 192 hours ]
    Relative bioavailability (secondarily measured by Cmax) between two perindopril 4 mg tablet formulations (test and reference formulations) under fasting condition. The Cmax was measured based on the plasma concentration of perindopril parent compound.

  2. Peak plasma concentration (Cmax)of perindoprilat [ Time Frame: 192 hours ]
    Relative bioavailability (secondarily measured by Cmax) between two perindopril 4 mg tablet formulations (test and reference formulations) under fasting condition. The Cmax was measured based on the plasma concentration of the active metabolite, perindoprilat.

  3. Time to achieve the peak plasma concentration (tmax)of perindopril parent compound [ Time Frame: 192 hours ]
  4. Time to achieve the peak plasma concentration (tmax)of perindoprilat [ Time Frame: 192 hours ]
  5. Elimination half-life (t1/2)of perindopril parent compound [ Time Frame: 192 hours ]
  6. Elimination half-life (t1/2)of perindoprilat [ Time Frame: 192 hours ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male and female subjects
  • Aged 18-55 years inclusive
  • A body mass index in the range of 18-25 kg/m2
  • Able to participate, communicate well with the investigators and willing to give informed consent
  • Non-smokers

  • Vital signs (after 10 minutes resting) are within the following ranges:

    • systolic blood pressure 100-125 mmHg
    • diastolic blood pressure 60-80 mmHg
    • pulse rate 60-90 bpm

Exclusion Criteria:

  • Pregnant or lactating women
  • Known hypersensitivity or contraindication to perindopril
  • Intake of any prescription drug within 14 days of this study's first dosing day
  • Intake of any non-prescription drug, food supplement, or herbal medicine within 7 days of this study's first dosing day
  • History or presence of any liver dysfunction (ALT, alkaline phosphatase, total bilirubin ≥ 1.5 ULN)
  • History of any bleeding or coagulation disorders
  • Clinically significant ECG abnormalities
  • Clinically significant haematology abnormalities
  • Renal insufficiency (plasma creatinine concentration ≥ 1.4 mg/dL)
  • Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of the study drug
  • A donation or loss of 500 mL (or more) of blood within 3 months before this study's first dosing day
  • A positive hepatitis B surface antigen (HBsAg), anti-HCV, and anti-HIV
  • History of drug or alcohol abuse within 12 months prior to screening of this study
  • Participation in a previous study within 3 months of this study's first dosing day
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01682577


Locations
Layout table for location information
Indonesia
PT Equilab International
Jakarta, Indonesia, 12430
Sponsors and Collaborators
Dexa Medica Group
Investigators
Layout table for investigator information
Principal Investigator: Danang A Yunaidi, MD PT. Equilab International
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications:

Layout table for additonal information
Responsible Party: Dexa Medica Group
ClinicalTrials.gov Identifier: NCT01682577    
Other Study ID Numbers: PR.122/EQL/2008
First Posted: September 11, 2012    Key Record Dates
Last Update Posted: September 11, 2012
Last Verified: September 2012
Keywords provided by Dexa Medica Group:
Perindopril
Perindoprilat
Bioequivalence
Pharmacokinetic
Angiotensin-converting enzyme inhibitor
Additional relevant MeSH terms:
Layout table for MeSH terms
Perindopril
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
 Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antihypertensive Agents